Share chart Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
About Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited вместе со своими дочерними компаниями занимается исследованием, разработкой, производством и продажей китайских патентованных и западных лекарств, химического сырья, натуральных и биологических лекарств и промежуточных продуктов химического сырья в Китайской Народной Республике. Китае и на международном уровне. Компания работает в четырех сегментах: Great Southern Medicine, Great Commerce, Great Health и Great Medical Care. more detailsISIN | CNE100000387 |
---|---|
Industry | Pharmaceuticals |
Sector | Health Care |
Валюта | hkd |
Валюта отчета | cny |
Див.доход ао | 3.99 |
Дивиденд ао | 1.26 |
Сайт | https://www.gybys.com.cn |
Цена ао | 18.08 |
Change price per day: | +0.7804% (17.94) |
---|---|
Change price per week: | +2.15% (17.7) |
Change price per month: | +4.03% (17.38) |
Change price per 3 month: | +0.1107% (18.06) |
Change price per half year: | -6.03% (19.24) |
Change price per year: | -13.29% (20.85) |
Change price per 3 year: | -11.8% (20.5) |
Change price per 5 year: | -30.6% (26.05) |
Change price per 10 year: | 0% (18.08) |
Change price per year to date: | -0.6593% (18.2) |
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
Institutions | Volume | Share, % |
---|---|---|
Vanguard International Stock Index-Total Intl Stock Indx | 3131267 | 1.42 |
Vanguard International Stock Index-Emerging Markets Stk | 2597825 | 1.18 |
DFA Emerging Markets Core Equity Portfolio | 1082000 | 0.49 |
Goldman Sachs Emerging Markets Equity Insights Fund | 1056000 | 0.48 |
DFA Investment Dimensions-DFA Emerging Mkts Value | 624000 | 0.28 |
Vanguard Intl Equity Index Fds-FTSE All World ex U.S. Index Fund | 502620 | 0.23 |
DFA Emerging Markets Small Cap Series | 456000 | 0.21 |
Nationwide Var Ins Tr-NVIT GS Emerging Markets Insights Fd | 444000 | 0.2 |
Schwab Strategic Tr-Schwab Emerging Markets Equity ETF | 251442 | 0.11 |
DFA Emerging Markets Series | 230000 | 0.1 |
ETF | Share, % | Profitability for 1 year, % | Dividends, % |
---|---|---|---|
Loncar China BioPharma ETF | 1.99 | 18434.25 | |
JPMorgan Diversified Return Emerging Markets Equity ETF | 0.04645 | 7.2 | 5.1761 |
![]() |
0.03462 | 17.02 | 3.40103 |
![]() |
0.03 | -34.73 | |
Franklin FTSE China ETF | 0.02432 | 14.5 | 3.35323 |
Dimensional Emerging Markets Core Equity 2 ETF | 0.00871 | 15.96 | 3.34087 |
Franklin FTSE Asia ex Japan ETF | 0.00778 | 14.43 | 2.66768 |
Vanguard ESG International Stock ETF | 0 | 6.39 | 3.07501 |
Head | Job title | Payment | Year of birth |
---|---|---|---|
Mr. Hong Li | GM & Executive Director | 1.63M | 1967 (58 years) |
Ms. Ning Cheng | Executive Vice Chairman | N/A | 1966 (59 years) |
Mr. Jun Yang | Executive Vice Chairman | N/A | 1970 (55 years) |
Mr. Changhai Wu | Deputy GM & Executive Director | 412.12k | 1966 (59 years) |
Ms. Juyan Liu | Executive Director | N/A | 1964 (61 year) |
Ms. Haoshan Zheng | Deputy GM & Director of Business Administration Department | N/A | 1976 (49 years) |
Ms. Xuezhen Huang | Secretary | N/A | 1974 (51 year) |
Address: China, Guangzhou, No. 45 Shamian North Street - open in Google maps, open in Yandex maps
Website: https://www.gybys.com.cn
Website: https://www.gybys.com.cn